PerkinElmer to Buy ViaCell for $300M to Expand Neonatal Screening Business | GenomeWeb
NEW YORK (GenomeWeb News) - PerkinElmer has agreed to buy ViaCell, a Cambridge, Mass.-based specialty stem cell company, for around $300 million, the companies said Monday.
ViaCell focuses on collecting and preserving umbilical cord blood stem cells, and Perkin Elmer said it expects the acquisition to “significantly expand” its neonatal and prenatal screening business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.